Keywords
Hepatocellular carcinoma
TCGA database
Submitted : 2024-07-10
Accepted : 2024-07-25
Published : 2024-08-09
Abstract
Objective: To analyze the expression and clinical significance of the zinc finger protein ZNF207 gene in liver hepatocellular carcinoma (LIHC) based on The Cancer Genome Atlas (TCGA) database. Methods: The mRNA sequencing data of 371 cases of primary liver cancer, 50 cases of normal tissues, and 3 cases of recurrent liver cancer were downloaded from the TCGA database. The corresponding clinical information of the 371 cases of hepatocellular carcinoma was subsequently analyzed. The difference in ZNF207 expression between normal and tumor tissues was analyzed using the UALCAN online database. The impact of ZNF207 expression on survival prognosis was assessed using the Kaplan-Meier method in R software. The GO and KEGG pathways of ZNF207 were analyzed. The Cox proportional hazards model was used to evaluate the prognostic factors of patients with LIHC. RT-qPCR was employed to verify the expression of ZNF207 in LIHC cells. Results: ZNF207 was highly expressed in LIHC tissues and HepG2 cells, with a significant difference (P < 0.05). Multivariate Cox regression analysis revealed that patients with high ZNF207 expression had a significantly shorter overall survival time compared to those with low ZNF207 expression (HR = 1.466, 95% CI: 1.011–2.126, P < 0.05). GO enrichment analysis suggested that ZNF207 may influence the onset and progression of hepatocellular carcinoma by regulating mRNA splicing and mRNA transcription processing through the spliceosome. KEGG pathway enrichment analysis indicated that ZNF207 might affect the onset and progression of hepatocellular carcinoma through mitophagy, mRNA surveillance, homologous recombination, spliceosome, and nuclear-cytoplasmic transport. Conclusion: The expression of ZNF207 may be an independent predictor of the prognosis of patients with LIHC and could influence the development of hepatocellular carcinoma through various gene functions and pathways. It has the potential to serve as a novel molecular marker for predicting the prognosis of hepatocellular carcinoma.
References
Jiang Y, Han QJ, Zhang J, 2019, Hepatocellular Carcinoma: Mechanisms of Progression and Immunotherapy. World J Gastroenterol, 25(25): 3151–3167. https://doi.org/10.3748/wjg.v25.i25.3151
Lin J, Wu L, Bai X, et al., 2016, Combination Treatment Including Targeted Therapy for Advanced Hepatocellular Carcinoma. Oncotarget, 7(43): 71036–71051. https://doi.org/10.18632/oncotarget.11954
Fang F, Xia N, Angulo B, et al., 2018, A Distinct Isoform of ZNF207 Controls Self-Renewal and Pluripotency of Human Embryonic Stem Cells. Nat Commun, 9(1): 4384. https://doi.org/10.1038/s41467-018-06908-5
Wang X, Zhou T, Chen X, et al., 2022, System Analysis Based on the Cancer-Immunity Cycle Identifies ZNF207 as A Novel Immunotherapy Target for Hepatocellular Carcinoma. J Immunother Cancer, 10(3): e004414. https://doi.org/10.1136/jitc-2021-004414
Zhou C, Li N, 2019, Expression and Significance of ZNF207 in Hepatocellular Carcinoma. Journal of Central South University Medicine, 44(4): 406–412.
Chandrashekar DS, Bashel B, Balasubramanya SAH, et al., 2017, UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia, 19(8): 649–658. https://doi.org/10.1016/j.neo.2017.05.002
Uhlén M, Fagerberg L, Hallström BM, et al., 2015, Proteomics. Tissue-Based Map of the Human Proteome. Science, 347(6220): 1260419. https://doi.org/10.1126/science.1260419
Lu G, Chen L, Wang H, 2015, The Present Situation and Prospect of Liver Cancer Research in Our Country. Life Sciences, 27(3): 237–248. https://doi.org/10.13376/j.cbls/2015034
Department of Medical Administration, National Health and Health Commission of the People’s Republic of China, 2020, Diagnostic and Therapeutic Criteria for Primary Liver Cancer (2019 Edition). Chinese Journal of Practical Surgery, 40(2): 121–138. https://doi.org/10.3760/cma.j.issn.1007-3418.2020.02.004
Lok AS, Sterling RK, Everhart JE, et al., 2010, Des-Gamma-Carboxy Prothrombin and Alpha-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma. Gastroenterology, 138(2): 493–502. https://doi.org/10.1053/j.gastro.2009.10.031
Bruix J, Sherman M, 2005, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma. Hepatology, 42(5): 1208–1236. https://doi.org/10.1002/hep.20933
Miller J, McLachlan AD, Klug A, 1985, Repetitive Zinc-Binding Domains in the Protein Transcription Factor IIIA from Xenopus Oocytes. EMBO J, 4(6): 1609–1614. https://doi.org/10.1002/j.1460-2075.1985.tb03825.x
Jen J, Wang YC, 2016, Zinc Finger Proteins in Cancer Progression. J Biomed Sci, 23(1): 53. https://doi.org/10.1002/j.1460-2075.1985.tb03825.x
Pahl PM, Hodges YK, Meltesen L, et al., 1998, ZNF207, A Ubiquitously Expressed Zinc Finger Gene on Chromosome 6p21.3. Genomics, 53(3): 410–412. https://doi.org/10.1006/geno.1998.5442